Partial remission of psoriasis following rituximab therapy f…

Established

15
Citations
6
Refs
2005
Year
Search Works
Work Details
  • PMID https://pubmed.ncbi.nlm.nih.gov/16268262
  • OpenAlex ID W2406300217
  • Type Article
  • Language EN
  • Published 01 Sep 2005
  • Volume 76 (3)
  • Pages 186–8
  • Source PubMed
  • Publisher National Institutes of Health
  • FWCI 0.59
  • Countries 1
  • Institutions 1
  • Added 24 Jun 2016
  • Updated 29 Sep 2026
External Links
OpenAlex Record PubMed Publisher Page
MENU
0

Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma.

Article 2005 EN

Rituximab, a human-mouse, chimeric, monoclonal antibody that targets the B-cell CD20 antigen and causes rapid and specific B-cell depletion, is indicated for the treatment of low-grade or follicular, relapsed or refractory, CD20+ B-cell, non-Hodgkin lymphoma (NHL). We report the case of a middle-aged woman with psoriasis who experienced a partial sustained remission of her psoriasis after treatmen…

15

Citations

6

References

2

Authors

0.59

FWCI

Citations by Year
Last 4 years
Topics
Keywords
UN Sustainable Development Goals
1 SDGs
Authors & Affiliations
2 authors
#AuthorInstitutionsORCID
1 Fiza Singh St. Luke's-Roosevelt Hospital … (US) —
2 Jeffrey M Weinberg — —
Related Works
10

Data: OpenAlex